Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.42 |
| ▸ | LPL | P06858 | 1/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 5/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22290622 | 0.82 | LPL (0.47) | LIPGLPLCARM1PRMT6PRMT8 | |
| SCHEMBL31173419 | 0.81 | CARM1 (0.49) | CARM1PRMT6PRMT8 | |
| SCHEMBL22290830 | 0.81 | CARM1 (0.49) | CARM1PRMT6PRMT8 | |
| SCHEMBL22291043 | 0.78 | LIPG (0.49) | LIPGLPLTDP2CARM1PRMT6 | |
| SCHEMBL1362568 | 0.74 | LIPG (0.50) | LIPGLPLCARM1PRMT6PRMT8 | |
| SCHEMBL24493122 | 0.74 | PRMT6 (0.35) | CARM1PRMT6PRMT8SSTR4 | |
| SCHEMBL22290349 | 0.73 | LIPG (0.49) | LIPGLPLTDP2CARM1PRMT6 | |
| SCHEMBL22290754 | 0.72 | LIPG (0.48) | LIPGLPLTDP2CARM1PRMT6 | |
| SCHEMBL19499255 | 0.72 | NTRK1 (0.42) | BACE1ROCK1SSTR4 | |
| SCHEMBL22290682 | 0.71 | LIPG (0.47) | LIPGLPLTDP2CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3917527-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113645971-A | Compound and use thereof | 福宏治疗公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | LIPG 2836/4885LPL 1810/4885TDP2 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.